A Phase I trial (NCT05060796) using EGFR-targeted CAR T-cells modified with CXCR5 for advanced NSCLC showed manageable toxicity, with one case of grade 3–4 hyperlipasemia. This evidence concerns the gene EGFR and non-small cell lung carcinoma.